Key Takeaways
- Aardvark Therapeutics reveals plans for an IPO, focusing on ARD-101 for appetite suppression.
- Ascentage Pharma enters the Nasdaq with a $126.4 million offering aimed at cancer drug development.
- Both companies underscore the growing interest in biotech IPOs as the market window gradually widens.
Aardvark Therapeutics Moves Toward IPO
Aardvark Therapeutics, a clinical-stage metabolic biotechnology firm, has announced its intention to go public amidst a surge of interest in biotech initial public offerings (IPOs) this January. The company is known for developing ARD-101, a TAS2R pan-agonist aimed at stimulating enteroendocrine cells in the digestive tract. The purpose of this drug is to induce the release of gut-peptide hormones, such as GLP-1 and cholecystokinin, which are significant in managing hunger. This mechanism is similar to that of popular weight loss medications from Novo Nordisk and Eli Lilly.
ARD-101 has demonstrated promise in clinical trials, exhibiting the ability to suppress appetite whether administered alone or alongside existing approved drugs. In three phase 2 studies, including one involving 20 patients with general obesity, participants receiving ARD-101 reported a 2.51-fold greater reduction in hunger compared to those on a placebo. Another trial on patients with Prader-Willi syndrome, a rare genetic condition characterized by insatiable appetite, indicated that 11 out of 12 subjects experienced significant hunger reduction within 28 days.
In addition to its existing clinical studies, Aardvark plans to initiate a phase 2 trial addressing severe hunger and obesity associated with craniopharyngioma, a type of brain tumor. Although the exact valuation for its upcoming IPO remains unspecified, Aardvark expects to utilize proceeds to further advance ARD-101’s clinical development as well as support work on another asset, ARD-201, a combination of ARD-101 and a DPP-4 inhibitor. Since its inception in 2021, Aardvark has accumulated approximately $129.1 million in funding, most recently securing $85 million in May 2024 from Decheng Capital.
Ascentage Pharma Enters Nasdaq
In a parallel development, Hong Kong-listed Ascentage Pharma is making its debut on the Nasdaq with a $126.4 million IPO. The company has structured its offering to potentially raise an additional $19 million if underwriters exercise their option to purchase over one million American depositary shares at the IPO price of $17.25 each.
Ascentage plans to allocate up to $60 million of the proceeds to support the approval process for its cancer drug, lisaftoclax, in China, while an additional $40 million is earmarked for the development of the kinase inhibitor olverembatinib in the U.S.
The ongoing interest in biotech IPOs is indicative of a gradually improving appetite within the market, despite the challenges faced by companies in the sector. Aardvark’s and Ascentage’s recent moves may signal a renewed enthusiasm among investors for innovative healthcare solutions, particularly in the realms of weight management and cancer treatment, as firms navigate the complexities of public offerings in the current economic landscape.
The content above is a summary. For more details, see the source article.